Lopci E, et al. - The aim of this trial was to evaluate the use of 68Ga-(PSMA) prostate-specific membrane antigen positron emission tomography / computed tomography (PET/CT) for the identification and risk stratification of prostate cancer (PCa) in patients with contraindications to or negative multiparametric magnetic resonance imaging (mpMRI). As revealed by receiver operating characteristic (ROC) analysis, the SUV_max (maximum standardized uptake value) and SUV_ratio (tumor SUV_max/background SUV_max) of Gleason score (GS) 7 lesions and GS 6 lesions could discriminate clinically-relevant prostate cancer (PCa) with an overall sensitivity of 100% in both cases and a specificity of 76% and 88%, respectively. Hence, 68Ga-PSMA PET/CT was shown to be useful for primary detection of PCa in a specific subset of men.